会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明公开
    • 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
    • 聚乙烯甘油-G-CSF结合物
    • KR1020080044639A
    • 2008-05-21
    • KR1020060113721
    • 2006-11-17
    • 동아쏘시오홀딩스 주식회사
    • 조영우유원영전현규최윤규장혜인김병문이성희강수형유무희
    • A61K31/765A61K38/17A61K47/48A61P35/00
    • A61K9/0019A61K31/77A61K47/60A61K31/765A61K38/17A61K47/50
    • A tribranched polyethylene glycol(PEG)-granulocyte colony stimulating factor(G-CSF) conjugate is provided to show continuous physiological activity due to increased half life of the G-CSF in blood and have increased stability from de-polyethyleneglycol phenomenon and aggregate generation. A method for preparing the conjugate is provided to minimize the generation of oligo-polyethylene glycol G-CSF conjugate. A tribranched PEG-G-CSF conjugate is represented by a formula(1) where a tribranched polyethylene glycol having an average molecular weight of a PEG unit in the conjugate of 200-45,000 Da and G-CSF are bonded to each other in a molar ratio of 1:1. In the formula(1), n is an integer from 1 to 1,000; m is an integer from 10 to 1,000; Z is a linker between the G-CSF and the PEG and is (CH2)s or (CH2)sNHCO(CH2)s(where s is an integer from 1 to 6); and Y is an amide bond generated by a coupling reaction between an NH2 functional group in the G-CSF and a functional group in the PEG derivative. A tribranched PEG derivative represented by a formula(2) is covalently bonded to the G-CSF to prepare the conjugate. A pharmaceutical composition for treating or preventing symptoms caused by decreased hematogenous functions or decreased immune response comprises the conjugate as an effective ingredient.
    • 提供三支聚乙二醇(PEG) - 粒细胞集落刺激因子(G-CSF)缀合物以显示连续的生理活性,这是由于血液中G-CSF的半衰期增加,并且具有从脱乙二醇现象和聚集产生增加的稳定性。 提供了一种制备缀合物的方法,以使聚乙二醇G-CSF缀合物的产生最小化。 三分支PEG-G-CSF缀合物由式(1)表示,其中在200-45,000Da和G-CSF的缀合物中具有PEG单元的平均分子量的三聚乙二醇以摩尔浓度彼此键合 比例为1:1。 式(1)中,n为1〜1000的整数, m为10〜1000的整数, Z是G-CSF和PEG之间的接头,是(CH2)s或(CH2)sNHCO(CH2)s(其中s是1至6的整数); 并且Y是通过G-CSF中的NH 2官能团与PEG衍生物中的官能团之间的偶联反应产生的酰胺键。 由式(2)表示的三分子PEG衍生物与G-CSF共价键合以制备缀合物。 用于治疗或预防由血液功能降低或免疫应答降低引起的症状的药物组合物包含缀合物作为有效成分。
    • 12. 发明公开
    • 개선된 방출 양상을 갖는 인간성장호르몬 지속제어 방출생분해성 고분자의 약학적 조성물 및 미립구 제형
    • 改良的可生物降解微生物组合物,适用于人类生长激素的控制释放及其配制
    • KR1020070107941A
    • 2007-11-08
    • KR1020060040534
    • 2006-05-04
    • 동아쏘시오홀딩스 주식회사
    • 조영우곽현희이건일박용만양희창김병문이성희강수형
    • A61K9/10A61K38/27
    • A61K47/6901A61K9/0002A61K47/54A61K47/61
    • A biodegradable microsphere composition for the controlled release of human growth hormone is provided to maintain stability, increase C_1day value and inhibit initial burst release of human growth hormone by using cyclodextrins and multivalent metal cation, so that the human growth hormone is continuously released. A biodegradable microsphere composition for the controlled release of human growth hormone comprises human growth hormone, cyclodextrins, multivalent metal cation, and biodegradable polyester polymer as a polymer carrier, and is prepared by forming a first emulsion by dispersing human growth hormone, cyclodextrins and multivalent metal cation in a droplet of surfactant, and dispersing the first emulsion in a droplet of an emulsifier, wherein the multivalent metal cation is ZnCO3, ZnSO4, ZnCl2, Zn3(C6H5O7)2, Mg(OH)2, MgCO3, Mg(OAc)2, MgSO4, MgCl2, Mg3(C6H5O7)2 or CaCO3 and the biodegradable polyester polymer is poly-L-lactic acid, poly-glycolic acid, poly-D-lactic acid-co-glycolic acid, poly-L-lactic acid-co-glycolic acid, poly-D,L-lactic acid-co-glycolic acid, poly-carprolactone, poly-valerolactone, poly-hydroxy butyrate or poly-hydroxy valerate.
    • 提供用于控制释放人生长激素的可生物降解的微球组合物以通过使用环糊精和多价金属阳离子来保持稳定性,增加C_1天值并抑制人生长激素的初始爆发释放,使得人生长激素被连续释放。 用于人生长激素受控释放的可生物降解的微球组合物包括人生长激素,环糊精,多价金属阳离子和作为聚合物载体的可生物降解聚酯聚合物,并且通过分散人生长激素,环糊精和多价金属形成第一乳液来制备 并将第一乳液分散在乳化剂液滴中,其中多价金属阳离子为ZnCO 3,ZnSO 4,ZnCl 2,Zn 3(C 6 H 5 O 7)2,Mg(OH)2,MgCO 3,Mg(OAc)2 ,MgSO 4,MgCl 2,Mg 3(C 6 H 5 O 7)2或CaCO 3,可生物降解的聚酯聚合物是聚-L-乳酸,聚乙醇酸,聚-D-乳酸 - 共 - 乙醇酸,聚L-乳酸共聚物 聚乙醇酸,聚-D,L-乳酸 - 共 - 乙醇酸,聚己内酯,聚戊内酯,聚羟基丁酸酯或聚羟基戊酸酯。
    • 14. 发明公开
    • 단백질 또는 펩타이드에 결합되는 다가지의 고분자유도체와 접합체
    • 多肽聚合物衍生和结合蛋白质或肽
    • KR1020030017908A
    • 2003-03-04
    • KR1020010051528
    • 2001-08-25
    • 동아쏘시오홀딩스 주식회사
    • 조영우김원근임중인박범수이성희김원배이강춘
    • C08G65/00
    • C08G65/00A61K9/1275A61K38/00A61K47/34A61K47/642A61K47/6813C08G65/34C08G65/4031C08G65/48
    • PURPOSE: A physiological highly active multibranched polymer derivative and a conjugate bonded with protein or peptide are provided to minimize the reduction of physiological activity of protein and to increase the solubility in vivo by reducing the number of the polymer derivative bonded to the physiological site of protein and to protect the molecular structure of protein against the enzyme, thereby improving the in vivo utilization rate of active protein or peptide. CONSTITUTION: The multibranched polymer derivative has a mean molecular weight of polyethylene glycol unit of 15,000-80,000 D and is represented by the formula 1, wherein R1, R2 and R3 are independent each another and are an alkyl group of C1-C6; n1, n2 and n3 are an integer of 100-500; and Z is an active radical. Preferably Z is COONHS or CONH-CH2CH2(OCH2CH2)n4OCOONHS, wherein n4 is an integer of 50-500. The protein-polymer or peptide-polymer joined compound is one obtained by joining the multibranched polymer derivative with protein or peptide. Preferably the bonding site of the joined compound is the amine group or N-terminal of lysine.
    • 目的:提供生理高活性多分支聚合物衍生物和与蛋白质或肽结合的缀合物,以最大限度地减少蛋白质的生理活性,并通过减少与蛋白质生理部位结合的聚合物衍生物的数量来增加体内溶解度 并保护蛋白质的分子结构免于酶,从而提高活性蛋白或肽的体内利用率。 构成:多分支聚合物衍生物的聚乙二醇单元的平均分子量为15,000-80,000D,由式1表示,其中R1,R2和R3彼此独立,为C1-C6烷基; n1,n2和n3为100-500的整数; 而Z是一个活跃的激进。 Z优选为COONHS或CONH-CH2CH2(OCH2CH2)n4OCOONHS,其中n4为50-500的整数。 蛋白质 - 聚合物或肽 - 聚合物连接的化合物是通过将多分支聚合物衍生物与蛋白质或肽接合而获得的化合物。 优选地,连接的化合物的结合位点是胺基或赖氨酸的N-末端。
    • 17. 发明公开
    • 폴리에틸렌 글리콜-인터페론 알파 접합체
    • 聚乙二醇干扰素ALPHA结合物
    • KR1020070110162A
    • 2007-11-16
    • KR1020060042937
    • 2006-05-12
    • 동아쏘시오홀딩스 주식회사
    • 조영우유원영전현규최윤규장혜인김병문이성희강수형
    • A61K38/21A61P35/00
    • A61K38/212A61K47/60
    • A polyethylene glycol-interferon alpha conjugate is provided to increase half-life of the interferon alpha in blood by minimizing physiological activity reduction of interferon alpha, and improve purity and production yield of the conjugate, thereby efficiently showing antiviral and anticancer activity of the conjugate. A conjugate of tri-branched polyethylene glycol having the average molecular weight of 400-45,000 dalton, and being represented by the formula(1) and interferon alpha has the antiviral and anticancer activity, wherein n is an integer from 1 to 1,000 and m is an integer from 10 to 1,000; Z is a linker between interferon alpha and polyethylene glycol and is alkylene group of (CH2)s or (CH2)sNHCO(CH2)s in which S is an integer from 1 to 6; and Y is an amide bond or a secondary amine structure produced by bonding a NH2 group in the interferon molecule with functional groups of polyethylene glycol derivatives.
    • 提供聚乙二醇 - 干扰素α缀合物以通过最小化干扰素α的生理活性降低来提高血液中干扰素α的半衰期,并提高缀合物的纯度和产量,从而有效显示缀合物的抗病毒和抗癌活性。 平均分子量为400-45,000道尔顿并由式(1)和干扰素α表示的三支化聚乙二醇的共轭物具有抗病毒和抗癌活性,其中n为1至1,000的整数,m为 从10到1000的整数; Z是干扰素α和聚乙二醇之间的连接体,并且是(CH 2)s或(CH 2)s NHCO(CH 2)s的亚烷基,其中S是1至6的整数; 并且Y是通过将干扰素分子中的NH 2基团与聚乙二醇衍生物的官能团结合而产生的酰胺键或仲胺结构。